業績紹介

2025年 論文

  • Karasawa H, Kosaka T, Komatsuda A, Baba Y, Nakamura K, Nishihara H, Oya M. Incidentally Detected Ductal Adenocarcinoma Presenting With Isolated Pulmonary Metastasis and a BRCA2 Mutation. IJU Case Rep. 2025 Nov 10;9(1):e70103. doi: 10.1002/iju5.70103. PMID: 41472903; PMCID: PMC12747786.
  • Taoka R, Fukuhara H, Miyake M, Kobayashi K, Ikeda A, Kanao K, Komai Y, Fujiwara R, Sato Y, Sugimoto M, Tsuzuki T, Fujimoto K, Inoue K, Oya M. Predictive Factors for Gastrointestinal and Hepatic Adverse Events During 5-Aminolevulinic Acid-Guided Photodynamic Diagnosis in Bladder Cancer: Exploratory Analysis of the Phase III SPP2C102 Trial. Int J Urol. 2026 Jan;33(1):e70328. doi: 10.1111/iju.70328. Epub 2025 Dec 25. PMID: 41449791.
  • Kosaka T, Kikuchi E, Mikami S, Miyajima A, Shirotake S, Ishida M, Okada Y, Oya M. Editor's Note: Expression of Snail in Upper Urinary Tract Urothelial Carcinoma: Prognostic Significance and Implications for Tumor Invasion. Clin Cancer Res. 2025 Dec 15;31(24):5318. doi: 10.1158/1078-0432.CCR-25-4109. Erratum for: Clin Cancer Res. 2010 Dec 1;16(23):5814-23. doi: 10.1158/1078-0432.CCR-10-0230. PMID: 41392645.
  • Konnai Y, Matsumoto K, Fukumoto K, Takeda T, Yasumizu Y, Tanaka N, Oya M. Pure Retroperitoneal Robot-Assisted Radical Nephroureterectomy (RANU): Initial Experience Using the Hinotori Surgical Robot System. Asian J Endosc Surg. 2025 Jan-Dec;18(1):e70174. doi: 10.1111/ases.70174. PMID: 41360723.
  • Osawa T, Matsubara N, Kato T, Shiota M, Nishimoto K, Abe T, Shinohara N, Yasumizu Y, Tanaka N, Oya M, Abutani H, Oda T, Fujisawa T, Nakamura Y, Sivakumar S, Eto M, Yoshino T, Nonomura N. Genomic alteration and clinical significance of circulating tumor DNA in patients with advanced urothelial cancer: SCRUM-Japan monstar screen project. NPJ Precis Oncol. 2025 Nov 18;9(1):362. doi: 10.1038/s41698-025-01154-7. PMID: 41254099; PMCID: PMC12627086.
  • Armstrong AJ, Saad F, Oya M, Vianna K, Özgüroğlu M, Gedye C, Buchschacher GL Jr, Lee JY, Emmenegger U, Navrátil J, Virizuela JA, Salazar A, Maillet D, Uemura H, Hosius C, McGuinness D, Degboe A, Clarke N. Patient-reported Outcomes for Men with Metastatic Castration-resistant Prostate Cancer Who Received Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Phase 3 PROpel Study. Eur Urol Oncol. 2026 Feb;9(1):80-92. doi: 10.1016/j.euo.2025.09.010. Epub 2025 Nov 17. PMID: 41253648.
  • Konnai Y, Fukumoto K, Takeuchi M, Takeuchi R, Fujiwara S, Yasumizu Y, Tanaka N, Takeda T, Matsumoto K, Kosaka T, Kawakubo H, Kitagawa Y, Oya M. ASO Author Reflections: Advancing AI-Based Surgical Phase Recognition in Robot-Assisted Radical Prostatectomy. Ann Surg Oncol. 2026 Feb;33(2):1900-1901. doi: 10.1245/s10434-025-18758-9. Epub 2025 Nov 13. PMID: 41233707.
  • Kamitani R, Morimoto K, Morita S, Arai E, Takenouchi T, Ubara Y, Oya M. A Case of TSC2/PKD1 Contiguous Gene Deletion Syndrome With Proven Kidney Pathology. Kidney Med. 2025 Sep 16;7(11):101108. doi: 10.1016/j.xkme.2025.101108. PMID: 41209173; PMCID: PMC12595369.
  • Saad F, Armstrong AJ, Oya M, Shore N, Procopio G, Guedes JD, Arslan C, Mehra N, Brown E, Joung JY, Sugimoto M, Sartor O, Poehlein C, Harrington EA, Kang J, Clarke N. Prostate-specific Antigen and Objective Response Analyses in PROpel: Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone as First-line Therapy for Metastatic Castration-resistant Prostate Cancer. Eur Urol Oncol. 2025 Nov 4:S2588-9311(25)00284-6. doi: 10.1016/j.euo.2025.10.010. Epub ahead of print. PMID: 41193272.
  • Ide H, Najafi MAE, Matsukawa T, Tatenuma T, Oya M, Miyamoto H. Expression of Glucocorticoid Receptor and FOXO1/phospho-FOXO1 in Bladder Cancer as Independent Prognosticators. Cancer Genomics Proteomics. 2025 Nov-Dec;22(6):850-862. doi: 10.21873/cgp.20542. PMID: 41151860; PMCID: PMC12577604.
  • Konnai Y, Fukumoto K, Takeuchi M, Takeuchi R, Fujiwara S, Yasumizu Y, Tanaka N, Takeda T, Matsumoto K, Kosaka T, Kawakubo H, Kitagawa Y, Oya M. Artificial- Intelligence-based Surgical Phase Recognition in Robot-Assisted Radical Prostatectomy and Cross-Surgeon Validation. Ann Surg Oncol. 2026 Feb;33(2):1870-1877. doi: 10.1245/s10434-025-18590-1. Epub 2025 Oct 21. PMID: 41120774.
  • Kamisawa K, Takeda T, Nishimoto Y, Tanigawa M, Fukumoto K, Yasumizu Y, Tanaka N, Matsumoto K, Morita S, Kosaka T, Asanuma H, Oya M. Predictors of Pentafecta Failure Despite Trifecta Achievement in Robot-Assisted Partial Nephrectomy. Asian J Endosc Surg. 2025 Jan-Dec;18(1):e70167. doi: 10.1111/ases.70167. PMID: 41120203; PMCID: PMC12540015.
  • Tanegashima T, Shiota M, Akamatsu S, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Matsuyama H, Obara W, Shinohara N, Fujimoto K, Nozawa M, Ohba K, Ohyama C, Hashine K, Kamba T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y, Mukai S, Ito K, Tokunaga S, Eto M; SNiP‐RCC investigators. GWAS Identifies SNPs Associated With Severe Adverse Events and Efficacy in Advanced Renal Cell Carcinoma Treated With Nivolumab. Cancer Sci. 2025 Dec;116(12):3300-3308. doi: 10.1111/cas.70204. Epub 2025 Sep 24. PMID: 40991840; PMCID: PMC12666458.
  • Komori T, Ide H, Fukada J, Baba Y, Matsumoto K, Miyamoto H, Oya M. Correction: Androgen receptor signaling induces hemorrhage and angiogenesis in the irradiated bladder. Sci Rep. 2025 Sep 12;15(1):32518. doi: 10.1038/s41598-025-18614-6. Erratum for: Sci Rep. 2025 Aug 11;15(1):29438. doi: 10.1038/s41598-025-15245-9. PMID: 40940505; PMCID: PMC12432220.
  • Kamatani T, Umeda K, Iwasawa T, Miya F, Matsumoto K, Mikami S, Hara K, Shimoda M, Suzuki Y, Nishino J, Kato M, Kakimi K, Tanaka N, Oya M, Tsunoda T. Clonal diversity shapes the tumour microenvironment leading to distinct immunotherapy responses in metastatic urothelial carcinoma. Nat Commun. 2025 Aug 27;16(1):7995. doi: 10.1038/s41467-025-63309-1. PMID: 40866351; PMCID: PMC12391455.
  • Mizowaki T, Hosono M, Uemura H, Eto M, Oya M, Miyake H, Ikeda M, Kanegasaki A, Sakuragi S, Oida Y, Kinuya S. [Evaluation of Appropriate Treatment Infrastructure for Radionuclide Therapy Through Discrete Event Simulation]. Kaku Igaku. 2025;62(1):59-70. Japanese. doi: 10.18893/kakuigaku.oa.2503. PMID: 40835475.
  • Komori T, Ide H, Fukada J, Baba Y, Matsumoto K, Miyamoto H, Oya M. Androgen receptor signaling induces hemorrhage and angiogenesis in the irradiated bladder. Sci Rep. 2025 Aug 11;15(1):29438. doi: 10.1038/s41598-025-15245-9. Erratum in: Sci Rep. 2025 Sep 12;15(1):32518. doi: 10.1038/s41598-025-18614-6. PMID: 40790154; PMCID: PMC12339939.
  • Shigeta K, Daimon T, Hongo H, Ku SY, Ozawa H, Haratake N, Fushimi A, Nakashoji A, Bhattacharya A, Takamori S, Kono M, Rokugo M, Baba Y, Kosaka T, Oya M, Jacobi J, Long MD, Beltran H, Kufe D. MUC1-C dependence in treatment- resistant prostate cancer uncovers a target for antibody-drug conjugate therapy. JCI Insight. 2025 Jun 24;10(14):e190924. doi: 10.1172/jci.insight.190924. PMID: 40553569; PMCID: PMC12288968.
  • Mikami S, Mizuno R, Tanaka N, Hakozaki K, Takamatsu K, Oya M. Increased Expression of AXL and c-MET in High-Grade Clear Cell Renal Cell Carcinoma and Its Association With VEGFR-TKI Treatment and PD-L1 Expression. Pathol Int. 2025 Aug;75(8):403-413. doi: 10.1111/pin.70030. Epub 2025 Jun 2. PMID: 40454929.
  • Yanai Y, Kosaka T, Mikami S, Takeda T, Matsumoto K, Masuda T, Oya M. Prognostic impact of extraprostatic extension on prostate cancer with seminal vesicle invasion. Am J Clin Exp Urol. 2025 Apr 25;13(2):186-193. doi: 10.62347/EDGZ4295. PMID: 40401002; PMCID: PMC12089220.
  • Saad F, Armstrong AJ, Shore N, George DJ, Oya M, Sugimoto M, McKay RR, Hussain M, Clarke NW. Olaparib Monotherapy or in Combination with Abiraterone for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) and a BRCA Mutation. Target Oncol. 2025 May;20(3):445-466. doi: 10.1007/s11523-025-01146-4. Epub 2025 May 21. PMID: 40397306; PMCID: PMC12106333.
  • Shigeta K, Kosaka T, Kitano S, Yasumizu Y, Miyazaki Y, Mizuno R, Shinojima T, Kikuchi E, Miyajima A, Tanoguchi H, Hasegawa S, Oya M. Correction to: High Absolute Monocyte Count Predicts Poor Clinical Outcome in Patients with Castration-Resistant Prostate Cancer Treated with Docetaxel Chemotherapy. Ann Surg Oncol. 2025 Aug;32(8):6199-6200. doi: 10.1245/s10434-025-17480-w. Erratum for: Ann Surg Oncol. 2016 Nov;23(12):4115-4122. doi: 10.1245/s10434-016-5354-5. PMID: 40342006.
  • Shigeta K, Matsumoto K, Kitaoka S, Omura M, Umeda K, Arita Y, Mikami S, Fukumoto K, Yasumizu Y, Tanaka N, Takeda T, Morita S, Kosaka T, Mizuno R, Hara S, Oya M. Corrigendum to "Profiling FGFR3 Expression Based on the Immune Micro- environment in Upper Tract Urothelial Carcinoma" [Eur. Urol. Oncol. 7(6) (2024) 1338-1349]. Eur Urol Oncol. 2025 Aug;8(4):1217-1218. doi: 10.1016/j.euo.2025.04.023. Epub 2025 May 6. Erratum for: Eur Urol Oncol. 2024 Dec;7(6):1338-1349. doi: 10.1016/j.euo.2024.01.013. PMID: 40335397.
  • Kato T, Shiota M, Nishimoto K, Matsubara N, Osawa T, Abe T, Yasumizu Y, Tanaka N, Yamamoto Y, Ishizuya Y, Abutani H, Bando H, Fujisawa T, Nakamura Y, Oya M, Shinohara N, Eto M, Yoshino T, Nonomura N. Prognostic significance of circulating tumor DNA alterations in advanced renal cell carcinoma from SCRUM- Japan MONSTAR-SCREEN: a nationwide genomic profiling project. Br J Cancer. 2025 Jul;133(1):111-120. doi: 10.1038/s41416-025-02985-8. Epub 2025 May 5. PMID: 40325148; PMCID: PMC12238367.
  • Oya M, Yasuoka S, Tokudome T, Minegishi T, Hamada M, Ozaki M, Maekawa S, Ito Y. Adverse events of hepatic function disorder in Japanese patients with radically unresectable or metastatic renal cell carcinoma treated with pembrolizumab plus axitinib: a post-marketing surveillance study. Int J Clin Oncol. 2025 Jun;30(6):1229-1236. doi: 10.1007/s10147-025-02708-2. Epub 2025 Apr 29. PMID: 40299253; PMCID: PMC12122596.
  • Shiota M, Nemoto S, Ikegami R, Tanegashima T, Blas L, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Kobayashi K, Obara W, Shinohara N, Fujimoto K, Nozawa M, Ohba K, Ohyama C, Hashine K, Akamatsu S, Motoshima T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y, Mukai S, Ito K, Eto M. Predictive Model of Objective Response to Nivolumab Monotherapy for Advanced Renal Cell Carcinoma by Machine Learning Using Genetic and Clinical Data: The SNiP-RCC Study. JCO Clin Cancer Inform. 2025 Apr;9:e2400167. doi: 10.1200/CCI-24-00167. Epub 2025 Apr 25. PMID: 40279530.
  • Yagi F, Akita H, Matsumoto K, Kosaka T, Ueno A, Nakamura S, Hasunuma Y, Taketani T, Okita H, Oya M, Jinzaki M. A case of plasmacytoid urothelial carcinoma with characteristic radiological findings. Abdom Radiol (NY). 2025 Nov;50(11):5376-5381. doi: 10.1007/s00261-025-04940-w. Epub 2025 Apr 11. PMID: 40214695.
  • Arai M, Tanaka N, Takamatsu K, Murakami T, Mikami S, Imamura T, Nakamura K, Nishihara H, Oya M. Prognostic impact and landscape of cellular CXCR5 chemokine receptor expression in clear-cell renal cell carcinoma. Cancer Immunol Immunother. 2025 Apr 10;74(5):166. doi: 10.1007/s00262-025-04020-4. PMID: 40208344; PMCID: PMC11985720.
  • Yagi F, Akita H, Matsumoto K, Arai E, Meng W, Furuya K, Senda S, Oya M, Jinzaki M. Correction to: A case of immunoglobulin G4-related disease with a urethral lesion diagnosed by radiological imaging before biopsy. Abdom Radiol (NY). 2025 Oct;50(10):5066-5067. doi: 10.1007/s00261-025-04851-w. Erratum for: Abdom Radiol (NY). 2025 Apr;50(4):1672-1678. doi: 10.1007/s00261-024-04594-0. PMID: 40116892.
  • Oya M, Joung JY, Lee JY, Sugimoto M, Choi YD, Hong JH, Uemura H, Nishimura K, Tsumura H, Kawakami S, Hirayama Y, Kwon TG, Kwak C, Suzuki H, Fujita T, Nii M, McGuinness D, Dujka M, Poehlein C, Saad F, Clarke N. Olaparib Plus Abiraterone in Asian Patients With Metastatic Castration-Resistant Prostate Cancer: PROpel Subset Analysis. Cancer Sci. 2025 Jun;116(6):1638-1647. doi: 10.1111/cas.16459. Epub 2025 Mar 18. PMID: 40099663; PMCID: PMC12127112.
  • Taoka R, Fukuhara H, Miyake M, Kobayashi K, Ikeda A, Kanao K, Komai Y, Fujiwara R, Sato Y, Sugimoto M, Tsuzuki T, Fujimoto K, Inoue K, Oya M. Efficacy of photodynamic diagnosis for non-muscle invasive bladder cancer: Exploratory subject-based analysis in a prospective, single-arm, multicenter phase III trial. Photodiagnosis Photodyn Ther. 2025 Jun;53:104554. doi: 10.1016/j.pdpdt.2025.104554. Epub 2025 Mar 12. PMID: 40086561.
  • Murata Y, Kosaka T, Nakamura K, Baba Y, Arai E, Yasumizu Y, Matsumoto K, Nishihara H, Oya M. A case of testicular dysgenesis syndrome with squamous cell carcinoma of the prostate harboring a CDK12 mutation. IJU Case Rep. 2025 Jan 2;8(2):125-128. doi: 10.1002/iju5.12824. PMID: 40034901; PMCID: PMC11872195.
  • Shiota M, Matsubara N, Kato T, Eto M, Osawa T, Abe T, Shinohara N, Nishimoto K, Yasumizu Y, Tanaka N, Oya M, Fujisawa T, Horasawa S, Nakamura Y, Yoshino T, Nonomura N. Genomic characterization of metastatic patterns in prostate cancer using circulating tumor DNA data from the SCRUM-Japan MONSTAR SCREEN project. J Liq Biopsy. 2024 Dec 20;7:100282. doi: 10.1016/j.jlb.2024.100282. PMID: 40027233; PMCID: PMC11863810.
  • Kuji S, Nozawa K, Toma S, Arao H, Imoto S, Kajiyama H, Kitano A, Kodera Y, Saito R, Sakai R, Taketomi A, Nakayama R, Hiyama E, Futamura M, Matsui M, Yonemura M, Oya M, Suzuki N. Survey of healthcare professionals' awareness of appearance care for Japanese cancer patients and their institutions' appearance care systems: report from the Japan Society of Clinical Oncology. Int J Clin Oncol. 2025 Apr;30(4):655-665. doi: 10.1007/s10147-024-02685-y. Epub 2025 Feb 17. PMID: 39960595.
  • Furukawa J, Kato T, Yamasaki T, Monji K, Tanaka T, Tsuchiya N, Miyagawa T, Yaegashi H, Sano T, Karashima T, Fujita K, Hori JI, Ito T, Kajita M, Tomita Y, Shinohara N, Eto M, Oya M, Uemura H. Real-world outcomes with avelumab + axitinib in patients with advanced renal cell carcinoma in Japan: subgroup analyses from the J-DART2 study by International Metastatic Renal Cell Carcinoma Database Consortium risk classification. Int J Clin Oncol. 2025 Apr;30(4):749-760. doi: 10.1007/s10147-024-02655-4. Epub 2025 Feb 11. PMID: 39934514; PMCID: PMC11946980.
  • Matsubara N, Osawa T, Abe T, Oya M, Nishimoto K, Iwahori T, Tsuchiya H, Murota M, Yoshida M, Tatematsu Y, Nakano Y, Eto M, Nonomura N. FGFR2/3 Gene Alterations and Clinical Outcomes in Advanced/Metastatic Urothelial Cancer in Japan: MONSTAR-SCREEN Database Study. Cancer Sci. 2025 May;116(5):1424-1432. doi: 10.1111/cas.70000. Epub 2025 Feb 11. PMID: 39933925; PMCID: PMC12044656.
  • Shibata M, Umezawa A, Aoto S, Okamura K, Nasu M, Mizuno R, Oya M, Yura K, Mikami S. Applicability of the regression approach for histological multi-class grading in clear cell renal cell carcinoma. Regen Ther. 2025 Jan 25;28:431-437. doi: 10.1016/j.reth.2025.01.011. PMID: 39925965; PMCID: PMC11802374.
  • Oya M, Ito T, Sato M, Morita M, Kajita M, Nonomura N. Avelumab + axitinib treatment in older patients with advanced renal cell carcinoma in Japan: Subgroup analyses of post-marketing surveillance data by age. Cancer Med. 2025 Jan;14(2):e70186. doi: 10.1002/cam4.70186. PMID: 39838508; PMCID: PMC11750686.
  • Nonomura N, Ito T, Sato M, Morita M, Ogi M, Kajita M, Oya M. Final Analysis of Post-Marketing Surveillance for Avelumab + Axitinib in Patients With Renal Cell Carcinoma in Japan. Cancer Med. 2025 Jan;14(2):e70275. doi: 10.1002/cam4.70275. PMID: 39838507; PMCID: PMC11750683.
  • Nonomura N, Ito T, Sato M, Morita M, Kajita M, Oya M. Post-marketing surveillance data for avelumab + axitinib treatment in patients with advanced renal cell carcinoma in Japan: Subgroup analyses by pathological classification. Int J Urol. 2025 Mar;32(3):293-299. doi: 10.1111/iju.15646. Epub 2024 Dec 19. PMID: 39699015; PMCID: PMC11923512.
  • Taoka R, Fujimoto K, Inoue K, Tsuzuki T, Oya M, Sugimoto M. Accuracy of photodynamic diagnosis for non-muscle-invasive bladder cancer: Exploratory analysis of anatomical locations and tumor types using data from a prospective, single-arm, multicenter phase III trial. Int J Urol. 2025 Mar;32(3):319-321. doi: 10.1111/iju.15653. Epub 2024 Dec 13. PMID: 39673232.
  • Yanai Y, Kosaka T, Mikami S, Arai M, Watanabe K, Takeda T, Matsumoto K, Yamashita M, Kitano S, Oya M. Dynamics in the Prostate Immune Microenvironment Induced by Androgen Deprivation Therapy. Prostate. 2025 Feb;85(3):308-314. doi: 10.1002/pros.24828. Epub 2024 Nov 24. PMID: 39580660; PMCID: PMC11720370.
  • Taoka R, Fukuhara H, Miyake M, Kobayashi K, Ikeda A, Kanao K, Komai Y, Fujiwara R, Sato Y, Sugimoto M, Tsuzuki T, Fujimoto K, Inoue K, Oya M. Correction to: Effect of extending the period from oral administration of 5-aminolevulinic acid hydrochloride to photodynamic diagnosis during transurethral resection for non-muscle invasive bladder cancer on diagnostic accuracy and safety: a single-arm multicenter phase III trial. Int J Clin Oncol. 2025 Jan;30(1):121-122. doi: 10.1007/s10147-024-02654-5. Erratum for: Int J Clin Oncol. 2025 Jan;30(1):110-120. doi: 10.1007/s10147-024-02638-5. PMID: 39560814; PMCID: PMC11700034.
  • Kato T, Furukawa J, Hinata N, Ueda K, Hara I, Hongo F, Mizuno R, Okamoto T, Okuno H, Ito T, Kajita M, Oya M, Tomita Y, Shinohara N, Eto M, Uemura H. Real- world outcomes of avelumab plus axitinib in patients with advanced renal cell carcinoma in Japan: long-term follow-up from the J-DART2 retrospective study. Int J Clin Oncol. 2025 Jan;30(1):99-109. doi: 10.1007/s10147-024-02618-9. Epub 2024 Nov 16. PMID: 39549218; PMCID: PMC11700049.
  • Yagi F, Akita H, Matsumoto K, Arai E, Meng W, Furuya K, Senda S, Oya M, Jinzaki M. A case of immunoglobulin G4-related disease with a urethral lesion diagnosed by radiological imaging before biopsy. Abdom Radiol (NY). 2025 Apr;50(4):1672-1678. doi: 10.1007/s00261-024-04594-0. Epub 2024 Sep 26. Erratum in: Abdom Radiol (NY). 2025 Oct;50(10):5066-5067. doi: 10.1007/s00261-025-04851-w. PMID: 39400591.
  • Clarke NW, Armstrong AJ, Oya M, Shore N, Procopio G, Daniel Guedes J, Arslan C, Mehra N, Parnis F, Brown E, Schlürmann F, Young Joung J, Sugimoto M, Sartor O, Poehlein C, McGuinness D, Degboe A, Saad F. Efficacy and Safety of Olaparib Plus Abiraterone Versus Placebo Plus Abiraterone in the First-line Treatment of Patients with Asymptomatic/Mildly Symptomatic and Symptomatic Metastatic Castration-resistant Prostate Cancer: Analyses from the Phase 3 PROpel Trial. Eur Urol Oncol. 2025 Apr;8(2):394-406. doi: 10.1016/j.euo.2024.09.013. Epub 2024 Oct 8. PMID: 39384451.
  • Taoka R, Fukuhara H, Miyake M, Kobayashi K, Ikeda A, Kanao K, Komai Y, Fujiwara R, Sato Y, Sugimoto M, Tsuzuki T, Fujimoto K, Inoue K, Oya M. Effect of extending the period from oral administration of 5-aminolevulinic acid hydrochloride to photodynamic diagnosis during transurethral resection for non- muscle invasive bladder cancer on diagnostic accuracy and safety: a single-arm multicenter phase III trial. Int J Clin Oncol. 2025 Jan;30(1):110-120. doi: 10.1007/s10147-024-02638-5. Epub 2024 Oct 7. Erratum in: Int J Clin Oncol. 2025 Jan;30(1):121-122. doi: 10.1007/s10147-024-02654-5. PMID: 39375287; PMCID: PMC11700051.
  • Yanai Y, Mikami S, Yasumizu Y, Takeda T, Matsumoto K, Kitano S, Oya M, Kosaka T. Loss of phosphatase and tensin homolog expression castration-sensitive prostate cancer predicts outcomes in men after prostatectomy. Int J Urol. 2025 Jan;32(1):39-44. doi: 10.1111/iju.15592. Epub 2024 Oct 1. PMID: 39352063; PMCID: PMC11730643.
業績紹介
慶應義塾大学泌尿器科学教室

160-8582 東京都新宿区信濃町35

TEL: 03-3353-1211（代表）

FAX: 03-3225-1985

  • 臨床研究へのご協力のお願い
  • NCDへのご協力のお願い
  • 慶應義塾大学病院
  • 慶應義塾大学医学部・医学研究科
  • 慶應義塾大学医学部 卒後臨床研修 専修医研修センター
  • 100周年
  • 慶應義塾大学
  • 三四会